A Phase 2, Single-center, Open-label, Randomized, Dose Ascending Trial to Evaluate the Efficacy and Safety of Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage Caused by Uterine Atony in Term Pregnant Women Having an Uncomplicated Vaginal Delivery
Latest Information Update: 20 May 2025
At a glance
Most Recent Events
- 20 May 2025 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health:NCT06968481).
- 13 May 2025 Status changed from planning to not yet recruiting.
- 28 Nov 2024 New trial record